MX2019014597A - Inhibidores de pirazolopirimidina de pde9. - Google Patents

Inhibidores de pirazolopirimidina de pde9.

Info

Publication number
MX2019014597A
MX2019014597A MX2019014597A MX2019014597A MX2019014597A MX 2019014597 A MX2019014597 A MX 2019014597A MX 2019014597 A MX2019014597 A MX 2019014597A MX 2019014597 A MX2019014597 A MX 2019014597A MX 2019014597 A MX2019014597 A MX 2019014597A
Authority
MX
Mexico
Prior art keywords
pyrazolopyrimidine
present
compounds
pde9
pde9 inhibitors
Prior art date
Application number
MX2019014597A
Other languages
English (en)
Inventor
Raghavan Subharekha
Arasappan Ashok
Tyagarajan Sriram
Li Derun
M Cox Jason
S Debenham John
Guo Zhuyan
He Jiafang
Hussain Zahid
Lai Zhong
Meng Dongfang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2019014597A publication Critical patent/MX2019014597A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

La presente invención se refiere a compuestos de pirazolopirimidina que pueden ser útiles como agentes terapéuticos para el tratamiento de trastornos asociados con la fosfodiesterasa 9 (PDE9). La presente invención también se refiere al uso de dichos compuestos para tratar enfermedades cardiovasculares y cerebrovasculares, tales como hipertensión, enfermedad renal crónica e insuficiencia cardíaca, y trastornos neurológicos y psiquiátricos, tales como esquizofrenia, psicosis o enfermedad de Huntington, y los asociados con hipofunción estriatal o disfunción de los núcleos basales.
MX2019014597A 2017-06-08 2018-06-06 Inhibidores de pirazolopirimidina de pde9. MX2019014597A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762516903P 2017-06-08 2017-06-08
US201862665840P 2018-05-02 2018-05-02
PCT/US2018/036172 WO2018226771A1 (en) 2017-06-08 2018-06-06 Pyrazolopyrimidine pde9 inhibitors

Publications (1)

Publication Number Publication Date
MX2019014597A true MX2019014597A (es) 2020-02-05

Family

ID=62779024

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014597A MX2019014597A (es) 2017-06-08 2018-06-06 Inhibidores de pirazolopirimidina de pde9.

Country Status (13)

Country Link
US (2) US10934294B2 (es)
EP (1) EP3634964B1 (es)
JP (1) JP2020523309A (es)
KR (1) KR20200013758A (es)
CN (1) CN111051308A (es)
AU (1) AU2018281131B2 (es)
BR (1) BR112019025813A2 (es)
CA (1) CA3064938A1 (es)
MA (1) MA53841A (es)
MX (1) MX2019014597A (es)
RU (1) RU2019144010A (es)
TW (1) TW201902898A (es)
WO (1) WO2018226771A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3634964B1 (en) 2017-06-08 2022-02-23 Merck Sharp & Dohme Corp. Pyrazolopyrimidine pde9 inhibitors
WO2020123271A1 (en) * 2018-12-12 2020-06-18 Merck Sharp & Dohme Corp. Cyclobutyl pyrazolopyrimidine pde9 inhibitors
CN114773256B (zh) * 2022-03-23 2024-05-03 中国农业大学 一种4-氰基哌啶的合成方法
CN117582909B (zh) * 2024-01-19 2024-04-02 天津凯莱英医药科技发展有限公司 一种连续生产5-单硝酸异山梨酯的***和方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE960442L (en) 1988-12-27 1990-06-27 Takeda Chemical Industries Ltd Guanidine derivatives, their production and insecticides
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
CA2417631A1 (en) 2000-08-01 2003-01-29 Bayer Aktiengesellschaft Selective pde 2 inhibitors, used as medicaments for improving cognition
US6770645B2 (en) 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
IL161155A0 (en) 2001-11-02 2004-08-31 Pfizer Prod Inc Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10328479A1 (de) 2003-06-25 2005-01-13 Bayer Ag 6-Arylamino-5-cyano-4-pyrimidinone
US8293754B2 (en) 2005-06-14 2012-10-23 Aska Pharmaceutical Co., Ltd. Thienopyrimidine derivatives
US8349850B2 (en) 2006-03-28 2013-01-08 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
EP2050739B1 (en) 2006-08-08 2016-07-06 ASKA Pharmaceutical Co., Ltd. Quinazoline derivative
ES2536906T3 (es) 2006-12-13 2015-05-29 Aska Pharmaceutical Co., Ltd. Derivado de quinoxalina
EP2152712B1 (en) 2007-05-11 2012-01-11 Pfizer Inc. Amino-heterocyclic compounds
WO2009068617A1 (en) 2007-11-30 2009-06-04 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-d) pyrimidin-4-one derivatives and their use as pde9a modulators for the teatment of cns disorders
US9089572B2 (en) 2008-01-17 2015-07-28 California Institute Of Technology Inhibitors of p97
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
WO2010026214A1 (en) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines and their use for the treatment of cns disorders
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
SI2414363T1 (sl) 2009-03-31 2014-04-30 Boehringer Ingelheim Gmbh Derivati 1-heterociklil-1,5-dihidro-pirazolo/3,4-d/pirimidin-4-ona in njihova uporaba kot modulatorji za PDE9A
TW201118099A (en) 2009-08-12 2011-06-01 Boehringer Ingelheim Int New compounds for the treatment of CNS disorders
MY170189A (en) * 2010-08-12 2019-07-09 Boehringer Ingelheim Int 6-cycloalkyl-1, 5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
JP5990106B2 (ja) 2011-01-28 2016-09-07 佐藤製薬株式会社 縮環化合物
US20130040971A1 (en) * 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
MX370433B (es) 2011-10-10 2019-12-13 H Lundbeck As Derivados de 7h-imidazo [1-5-a] pirazin-8-ona como inhibidores de la fosfodiasterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos.
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
KR101706216B1 (ko) 2012-04-03 2017-02-13 한화테크윈 주식회사 고밀도 삼차원 영상 재구성 장치 및 방법
WO2014024125A1 (en) 2012-08-08 2014-02-13 Celon Pharma S.A. Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
US10174032B2 (en) 2014-05-05 2019-01-08 Signalrx Pharmaceuticals, Inc. Heterocyclic compound classes for signaling modulation
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016209749A1 (en) 2015-06-25 2016-12-29 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
WO2017019723A1 (en) 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Aza-cyanoquinolinone pde9 inhibitors
WO2017019726A1 (en) 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Oxy-cyanoquinolinone pde9 inhibitors
WO2017019724A1 (en) 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Phenyl-cyanoquinolinone pde9 inhibitors
EP3634964B1 (en) * 2017-06-08 2022-02-23 Merck Sharp & Dohme Corp. Pyrazolopyrimidine pde9 inhibitors

Also Published As

Publication number Publication date
US20200140445A1 (en) 2020-05-07
US11028092B2 (en) 2021-06-08
BR112019025813A2 (pt) 2020-07-07
TW201902898A (zh) 2019-01-16
CA3064938A1 (en) 2018-12-13
MA53841A (fr) 2021-09-22
WO2018226771A1 (en) 2018-12-13
RU2019144010A3 (es) 2021-10-01
KR20200013758A (ko) 2020-02-07
EP3634964A1 (en) 2020-04-15
RU2019144010A (ru) 2021-07-13
US20180354955A1 (en) 2018-12-13
JP2020523309A (ja) 2020-08-06
AU2018281131A1 (en) 2019-12-05
AU2018281131B2 (en) 2022-01-20
US10934294B2 (en) 2021-03-02
CN111051308A (zh) 2020-04-21
EP3634964B1 (en) 2022-02-23

Similar Documents

Publication Publication Date Title
TN2014000070A1 (en) Pyrimidine pde10 inhibitors
MX2019014597A (es) Inhibidores de pirazolopirimidina de pde9.
MX2017011935A (es) Compuestos de triazolil pirimidinona como inhibidores de la enzima fosfodiesterasa 2 (pde2).
WO2012044562A3 (en) Pyrazolopyrimidine pde10 inhibitors
WO2012044561A3 (en) 2-alkoxy pyrimidine pde10 inhibitors
WO2012054366A3 (en) Substituted amino-triazolyl pde10 inhibitors
WO2016100162A3 (en) 5,5-bicyclic oxazole orexin receptor antagonists
MX2018003351A (es) Derivados de pirazolopirimidina como inhibidores de la btk para el tratramiento de cancer.
MX2015008860A (es) Inhibidores de 3-(benzoimidazol-2-il)-indazol de la senda de señalizacion de wnt y usos terapeuticos de los mismos.
EA201190303A1 (ru) ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-а]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДУПРЕЖДЕНИЯ НЕВРОЛОГИЧЕСКИХ И ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ
PH12019501074A1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
EA201891067A1 (ru) [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНОЕ СОЕДИНЕНИЕ
MY193511A (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
PH12018502378A1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
MX2017005284A (es) Nuevos derivados de pirazolopirimidina de la cinasa inductora de nf-kb (nk).
JOP20210164A1 (ar) طرق وتركيبات علاج السرطان
MX2021007260A (es) Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales.
SA520420768B1 (ar) مركبات بنزين سلفوناميد واستخدامها كعوامل علاجية
WO2014150114A8 (en) Substituted pyridizinone derivatives as pde10 inhibitors
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
AU2020288559A8 (en) Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
MX2019014665A (es) Nuevos derivados de azaindolina sustituida como inhibidores de nik.
MXPA05012081A (es) Derivados de pirimidina sustituidos.
AU2022238805B2 (en) Pro drugs of pde10 compounds
AR112073A1 (es) Inhibidores de pirazolopirimidina de pde9